Skip to playerSkip to main content
  • 9 years ago
Swiss drug maker Roche Holding AG, which missed a patent renewal deadline for its Herceptin has said that it was voluntary decision to let it lapse. Mint's CH Unnikrishnan explains the company's game plan

Category

🗞
News

Recommended